Arrowhead Pharmaceuticals · 1 day ago
Associate Scientist I, Buffer Prep
Arrowhead Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative drugs for diseases with a genetic basis. The Associate Scientist I will assist in the large scale preparation of buffers for oligonucleotide purification while ensuring compliance with GLP/GMP protocols.
BiotechnologyHealth CareNanotechnologyPharmaceutical
Responsibilities
Follow batch records, SOPs, and work instructions to detail
Document all operations in batch records and logbooks
Comply with GMP protocols
Operate large scale oligonucleotide manufacturing equipment (i.e. buffer prep tanks, HMIs, oligonucleotide synthesizer, purification skid, tangential flow filtration system, lyophilizer, ChemGlass reactors, pH/conductivity meters, peristaltic pumps, etc.)
Assist other chemists as needed within the Manufacturing group during synthesis and purification of oligonucleotides including:
Reagent solution preparation
Mobile phase preparation
Column Packing
Fraction collection
Communicate with cross-functional groups such as Process Development, Analytical Development, Quality Control, Quality Assurance, etc
Maintain a clean work space
Maintain safety by wearing required personal protective equipment
Track and update raw material usage in D365 ERP software
Qualification
Required
Bachelor of Science or appropriate, related work experience in a similar position
Excellent oral and written communication skills
Self-motivated team player with the ability to thrive in a fast paced, multi-disciplinary, matrixed environment
Preferred
Experience working in a GMP setting with controlled documentation
Benefits
Competitive salaries
Excellent benefit package
Company
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Funding
Current Stage
Public CompanyTotal Funding
$1.62BKey Investors
Sarepta TherapeuticsSixth StreetSilence Therapeutics
2024-11-26Post Ipo Equity· $325M
2024-08-08Post Ipo Debt· $400M
2024-01-03Post Ipo Equity· $450M
Leadership Team
Recent News
2026-01-07
Company data provided by crunchbase